「design controls」の検索結果

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing, reviewing, or implementing Settings/Preferences for Apple-platform apps — what belongs in Settings vs Inspector/Toolbar, grouped forms, native controls, secure storage, launch at login, and destructive actions.

日本語の概要は準備中です。原文の説明を表示しています。

Reviews a proposal, business case, deck or plan in character as a Chief Technology Officer archetype and returns a DRAFT review in the chat with a verdict, findings cited to the exact passage, technology risks (architecture, build versus buy, vendor lock-in, security of design, engineering capacity), what would change the verdict and five interrogation questions. Use when the user asks to "run a CTO review", "pressure-test the technical side of this plan", "what would a CTO ask about this" or "rehearse the technology seat before the review". Do not use for cash, payback or budget questions, use cfo-reviewer instead; for capacity and timeline questions, use coo-reviewer; for security controls, privacy or compliance, use ciso-reviewer. Drafts for human review; never approves, authorises or signs off.

日本語の概要は準備中です。原文の説明を表示しています。

Operational safety for deployless repositories. Use after mainline deployment and runtime release controls are designed, when a repo needs traces, replay tests, observability, rollback drills, smoke checks, compatibility windows, or expand-contract migration safety.

日本語の概要は準備中です。原文の説明を表示しています。

Use for release-level accessibility and performance review, including WCAG 2.2 AA, keyboard/focus, target size, reduced motion, semantic controls, Core Web Vitals, images/fonts/JavaScript, and animation or 3D performance budgets.

日本語の概要は準備中です。原文の説明を表示しています。

Design scalable SEO page systems using templates, structured data sources, quality thresholds, internal linking, indexation controls and anti-thin-content gates.

日本語の概要は準備中です。原文の説明を表示しています。

Design a test strategy around product risk, business invariants, failure modes, and existing controls, deciding what deserves testing and at which boundary rather than maximising coverage. Use whenever the user asks how to test something, wants a test plan or strategy, is deciding between unit/integration/contract/E2E/property/concurrency testing, or wants to know whether existing tests actually protect what matters. Prefer this over writing tests immediately. Part of the audit suite; inherits the shared constitution while its own job is proving risk coverage.

日本語の概要は準備中です。原文の説明を表示しています。

Run structured AI red team exercises for jailbreak resistance, data exfiltration risk, harmful output controls, and agent tool abuse resilience.

日本語の概要は準備中です。原文の説明を表示しています。

Secure AI agents against prompt injection, tool abuse, and data exfiltration with defense-in-depth controls.

日本語の概要は準備中です。原文の説明を表示しています。

Survey one surface of tdmcp (artist controls, library/packaging, CLI/DX, AI/LLM, or TouchDesigner depth) for candidate NEW features — inventory what exists, cross-check the roadmap, apply the gap-finding lenses, vet each idea, and emit a structured, novelty- and confidence-labelled candidate list to _workspace/discovery/. Use when a td-surveyor agent is scouting a surface during the feature-discovery harness.

日本語の概要は準備中です。原文の説明を表示しています。

Design App Intents, app entities, and App Shortcuts for iOS system surfaces. Use when exposing app actions or content to Shortcuts, Siri, Spotlight, widgets, or controls.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Implement hooks for permission control and security in custom agents. Use when adding security controls, blocking dangerous operations, implementing audit trails, or designing permission governance.

日本語の概要は準備中です。原文の説明を表示しています。

Corrects fluorophore spillover (conventional compensation) or spectral overlap (spectral unmixing) and applies variance-stabilizing transforms (logicle/biexponential, arcsinh, log) for flow and mass cytometry. Covers spillover-matrix estimation from single-stain controls, AutoSpill, the spillover spreading matrix and why panel design (not compensation) bounds resolution, compensate-then-transform ordering, and arcsinh cofactor choice (5 for CyTOF, ~150 for fluorescence, per-channel via flowVS). Use when correcting spectral overlap, preparing data for gating/clustering, choosing logicle vs arcsinh, deciding a cofactor, or distinguishing compensation from spectral unmixing.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Map controls to SOC2, ISO 27001, PCI, or internal policy for the org you work for. Evidence and control design — not audit theater.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Corrects fluorophore spillover (conventional compensation) or spectral overlap (spectral unmixing) and applies variance-stabilizing transforms (logicle/biexponential, arcsinh, log) for flow and mass cytometry. Covers spillover-matrix estimation from single-stain controls, AutoSpill, the spillover spreading matrix and why panel design (not compensation) bounds resolution, compensate-then-transform ordering, and arcsinh cofactor choice (5 for CyTOF, ~150 for fluorescence, per-channel via flowVS). Use when correcting spectral overlap, preparing data for gating/clustering, choosing logicle vs arcsinh, deciding a cofactor, or distinguishing compensation from spectral unmixing.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for developing cross-platform desktop applications with Avalonia UI framework. Use when building, debugging, or optimizing Avalonia apps including MVVM architecture, XAML design, data binding, styling, theming, custom controls, and cross-platform deployment for Windows, macOS, Linux, iOS, Android, and WebAssembly.

日本語の概要は準備中です。原文の説明を表示しています。

Design focused empty states for zero-data, no-results, permission, and error situations with clear value framing, strong CTAs, and less dead chrome. Use when the user mentions blank pages, zero-data screens, no results, permission states, or dead controls—not broader onboarding strategy.

日本語の概要は準備中です。原文の説明を表示しています。

Design and implement observability and SRE controls including SLO/SLI, OpenTelemetry instrumentation, alerting, dashboards, and incident readiness. Use when tasks involve telemetry coverage, operational reliability metrics, incident response, or runbook quality.

日本語の概要は準備中です。原文の説明を表示しています。

Design and enforce privacy and data protection controls across application, API, and database layers. Use when tasks involve PII handling, retention/deletion policies, consent, data minimization, auditability, or compliance-oriented architecture changes.

日本語の概要は準備中です。原文の説明を表示しています。